Advertisement
Screener

PRECIGEN, INC. (PGEN) Overview

PRECIGEN, INC. (PGEN) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 0.05; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.02; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -1.06; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.09; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$2.95$3.64$4.49$5.54$6.85$8.452025-09-292026-09-29$0.64$1.07$1.79$3.00$5.04$8.452021-09-292026-09-29$0.64$1.41$3.12$6.92$15.34$33.992016-09-292026-09-29$0.64$1.64$4.21$10.82$27.81$71.502013-08-082026-09-29$0.64$1.64$4.21$10.82$27.81$71.502013-08-082026-09-29

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$8.05
Previous close
$7.81
Change
$0.24
Change (%)
3.07%
Close date
2026-09-29
Previous close date
2026-09-28
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

PGEN
+92.58%
S&P 500
(m)

1 year

PGEN
+121.76%
S&P 500
(m)

3 years

PGEN
+466.90%
S&P 500
(m)

5 years

PGEN
+58.78%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual 0.05

-1.14-0.80-0.46-0.110.2331 Mar 2025: estimate (m); actual -0.1831 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.0930 Jun 2025(m)30 Sept 2025: estimate (m); actual -1.0630 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.0231 Mar 2026(m)30 Jun 2026: estimate (m); actual 0.0530 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)0.05(m)(m)
1 Jan 202631 Mar 2026(m)-0.02(m)(m)
1 Jul 202530 Sept 2025(m)-1.06(m)(m)
1 Apr 202530 Jun 2025(m)-0.09(m)(m)
1 Jan 202531 Mar 2025(m)-0.18(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -1.37

-1.45-1.01-0.57-0.120.3231 Dec 2021: estimate (m); actual -0.4731 Dec 2021(m)31 Dec 2022: estimate (m); actual 0.1431 Dec 2022(m)31 Dec 2023: estimate (m); actual -0.3931 Dec 2023(m)31 Dec 2024: estimate (m); actual -0.4731 Dec 2024(m)31 Dec 2025: estimate (m); actual -1.3731 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-1.37(m)(m)
1 Jan 202431 Dec 2024(m)-0.47(m)(m)
1 Jan 202331 Dec 2023(m)-0.39(m)(m)
1 Jan 202231 Dec 2022(m)0.14(m)(m)
1 Jan 202131 Dec 2021(m)-0.47(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 54.98M ■ Earnings 20.07M — Profit margin 36.51%

-67.25M-4039.3%-22.14M-2680.3%22.97M-1321.4%68.07M37.5%31 Mar 2025: revenue 1.34M; earnings -54.15M; profit margin -4038.26%31 Mar 202530 Jun 2025: revenue 0.86M; earnings -26.64M; profit margin -3112.38%30 Jun 202531 Mar 2026: revenue 23.25M; earnings -7.93M; profit margin -34.10%31 Mar 202630 Jun 2026: revenue 54.98M; earnings 20.07M; profit margin 36.51%30 Jun 2026

31 Dec 2025 ■ Revenue 9.68M ■ Earnings -250.60M — Profit margin -2587.77%

-284.07M-3216.3%-168.79M-2108.8%-53.51M-1001.3%61.77M106.2%31 Dec 2022: revenue 26.91M; earnings 28.30M; profit margin 105.17%31 Dec 202231 Dec 2023: revenue 6.22M; earnings -95.90M; profit margin -1540.56%31 Dec 202331 Dec 2024: revenue 3.92M; earnings -126.20M; profit margin -3215.29%31 Dec 202431 Dec 2025: revenue 9.68M; earnings -250.60M; profit margin -2587.77%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$8.05(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$8.05High(m)Average(m)Low(m)2025-09-292026-09-29

Recent news

View more →

(m)

YouTube videos mentioning PGEN

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-12; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$-157.66M
Profit margin
-183.93%
Return on assets · 12 month
-115.85%
Index membership
(m)
Employees
134.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
4.32M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
2.03%*
Total return · month
15.83%*
Total return · quarter
35.98%*
Total return · half year
119.35%*
Total return · year to date
92.58%*
Total return · 1 year
121.76%*
Total return · 3 years
466.90%*
Total return · 5 years
58.78%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$85.72M
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

PRECIGEN, INC. Overview

View more →

(m)

(m)

SEC CIK
1356090
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, Maryland, 20876, United States
Fiscal year end
1231
Phone
301-556-9900

Similar stocks

Stock NameCountryMarket CapPE Ratio
NewAmsterdam Pharma Co N.V. (NAMS)$2.719B-15.37
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Immunome Inc. (IMNM)United States$2.538B-9.45
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
uniQure N.V. (QURE)$2.416B-4.93
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67